Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients
Autor: | Clarisse Chavanne, Navita L. Mallalieu, Valerie Cosson, Elena Guerini, Mona Arab‐Alameddine, Michael Derks, Franziska Schaedeli-Stark |
---|---|
Rok vydání: | 2018 |
Předmět: |
education.field_of_study
Allosteric modulator business.industry General Neuroscience Population Cmax General Medicine Pharmacology medicine.disease 030226 pharmacology & pharmacy General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Metabotropic glutamate receptor Oral administration medicine Major depressive disorder General Pharmacology Toxicology and Pharmaceutics Adverse effect business education 030217 neurology & neurosurgery |
Zdroj: | Clinical and Translational Science. 11:523-531 |
ISSN: | 1752-8054 |
DOI: | 10.1111/cts.12566 |
Popis: | Dizziness, the most frequently observed adverse event in patients with major depressive disorder, was observed with basimglurant, a selective, orally active metabotropic glutamate receptor subtype 5 negative allosteric modulator. The potential relationship between dizziness and basimglurant exposure was explored. The pharmacokinetics of basimglurant was characterized with nonlinear mixed effects modeling using data from 288 trial participants enrolled in five clinical trials. The pharmacokinetics of basimglurant after daily oral administration of a modified release formulation was best described by a two-compartment disposition model with a transit compartment, lag time for the absorption, and first-order elimination. The largest covariate effects were the effect of smoking and male gender on apparent clearance followed by the effect of body weight on distribution volumes. Clearance was twofold higher in smokers and 40% higher in males. A logistic regression model showed a statistically significant correlation between basimglurant Cmax and incidence of dizziness. An increased risk of dizziness is predicted with increasing doses. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |